About Atomoxetine Hydrochloride API
Therapeutic CategoryCentral Nervous System (CNS)
CAS Number
82248-59-7
API Technology
Synthetic
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Canada DMF
Mechanism of Action
The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake and neurotransmitter depletion studies.
Indication
STRATTERA is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
Related APIs
Eslicarbazepine Acetate-es
Central Nervous System (CNS)
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!